Foundation Medicine, Inc.
Boston, MA
- UEI
- EHXPZ92G4AD1
- CAGE
- 73CG0
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Roche Holdings Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- YCFMJNG31TN3
- South San Francisco, CA F7F8GZXL7Q93
- South San Francisco, CA SA85BMHCTXK5
- Little Falls, NJ J28SZXJLMNB8
- FSJ4VFEVB5Q7
- ESP3ABJZP433
- Indianapolis, IN F6JDDN8L9JM4
- JWKEHKFXAB28
- Indianapolis, IN JDMDFEZBYH36
- NZKVNV4ELZM4
- NTU7TDTQBCZ5
- JJTLMFNTGKF4
- Monza, Lombardia CRBLKCZC9XC6
- YLL7KTH6P9C6
- LUKLLJTL2S86
- XML8DAL97854
- QF1UC7LVHM99
-
- SAM.gov registration date
- Physical address
- 400 Summer St, Boston, MA 02210, USA
- Website
- foundationmedicine.com
- Founded
- 2010
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $19,162,860 |
| FY2025 | $47,856,936 |
| FY2024 | $21,747,615 |
| FY2023 | $19,192,778 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $19,162,860 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Natera Inc. | Austin, TX | 621511 Medical Laboratories |
| Broad Clinical Laboratories, LLC | Cambridge, MA | 621511 Medical Laboratories |
| Personalis, Inc. | Fremont, CA | 541380 Testing Laboratories and Services |
| Biocartis US Inc. | Itasca, IL | 334516 Analytical Laboratory Instrument Manufacturing |
| Naveris Inc. | Waltham, MA | 621511 Medical Laboratories |
About the company
Foundation Medicine, Inc., a foreign-owned for-profit molecular diagnostics company headquartered in Boston, Massachusetts, delivers comprehensive genomic profiling and next-generation sequencing testing services exclusively to the Department of Veterans Affairs as a prime contractor, competing without set-asides and operating no subcontractors on federal work.
Foundation Medicine's federal footprint is dominated by VA precision oncology and hematologic malignancy testing. The company holds a $130.7 million single-award indefinite-delivery contract (36C10G24D0059) with VA Headquarters running through September 2027, which requires analysis of a minimum 5,000 tumor samples annually and accounts for the bulk of its federal potential value. A second $223.4 million parent IDC (36C10G19D0032) also anchors VA work. Recent task orders include a $22 million delivery order awarded September 22, 2026 for tumor molecular testing under the National Precision Oncology Program (completion September 12, 2028), a $24 million base-year delivery order for comprehensive genomic profiling awarded October 2, 2024 (completion September 12, 2025), and a $336,500 definitive contract awarded September 23, 2026 by Veterans Integrated Service Network 10 for hematologic malignancies testing with performance in Indianapolis, Indiana (completion August 31, 2031). Work is performed at Foundation Medicine locations in Boston and East Cambridge, Massachusetts, and Durham, North Carolina, with services delivered across all 132 VA oncology facilities nationwide.
VA Headquarters dominates customer concentration, accounting for 13 awards and $642.7 million of the combined potential value across Foundation Medicine's 63 prime awards. The top five funding entities represent 73% of award count but the concentration by dollar value is extreme—VA Headquarters alone represents 100% of combined potential value when rounded, with regional VISN awards totaling only $1.1 million across 46 awards. The portfolio spans 14 distinct customer agencies, but Navy Bureau of Medicine and Surgery (5 awards, $17 thousand) represents the only material non-VA customer by count. Place of performance is heavily concentrated in Massachusetts and regional VA medical centers, with subordinate performance locations including Indianapolis, Cleveland, Fredericksburg, Clarksburg, and Shreveport.
SCI-reported invoiced revenue on federal service contracts totaled $59.2 million across FY2023 and FY2025 ($20.4 million in FY2023, $38.8 million in FY2025). The SCI dataset shows Foundation Medicine reported zero FTEs across all fiscal years in the source period—a data artifact reflecting the nature of reference laboratory testing services, which SCI captures as materials or consumables delivery rather than labor. No subcontractors appear on any federal award, and across SCI-reportable prime contracts the average sub-hours share is zero percent, indicating Foundation Medicine builds and delivers its own testing infrastructure without reliance on subcontractor labor.
The three awards reaching ultimate completion in the next twenty-four months carry combined potential value of $153 million, creating meaningful recompete exposure. Activity has declined from six awards in 2022 to three in 2026, though the dollar value per award has increased substantially. Foundation Medicine is a subsidiary of Roche Diagnostics, a foreign-owned parent with 18 named subsidiaries including Genentech, Kapa Biosystems, Bioveris Corporation, Roche Nimblegen, and others spanning diagnostics, manufacturing, and life sciences research. The corporate structure reflects Roche's vertical integration in molecular diagnostics and genomic testing capabilities, positioning Foundation Medicine as the precision oncology testing arm serving federal health systems.
Quick answers
Is Foundation Medicine, Inc. registered in SAM.gov?
Yes. Foundation Medicine, Inc.'s SAM.gov registration is active through April 8, 2027.
How much has Foundation Medicine, Inc. received in federal contracts?
Federal contracts obligated $47,856,936 to Foundation Medicine, Inc. in fiscal year 2025 and $107,960,189 in fiscal years 2023 through 2027.
How does Foundation Medicine, Inc. rank among federal contractors?
Foundation Medicine, Inc.'s parent company, Roche Holdings Inc., ranked #3 in NAICS 6215, #3 in PSC Q3 and #16 in NAICS 621 in FY2025.
What is Foundation Medicine, Inc.'s most recent federal award?
Foundation Medicine, Inc.'s most recent federal contract award is Hematologic malignancies testing (36C25026C0159), from Veterans Integrated Service Network 10 (VHA), on September 23, 2026.
On GovTribe
See Foundation Medicine, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors